Cargando…

Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19

A novel human coronavirus SARS‐CoV‐2 (also referred to as CoV-19) that emerged in late 2019 causes Covid-19 disease a respiratory tract infection which provokes about 4 million deaths per year. Unfortunately, to date, there is no specific antiviral treatment for COVID-19. Mast cells (MCs) are immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Gigante, Antonio, Aquili, Alberto, Farinelli, Luca, Caraffa, Alessandro, Ronconi, Gianpaolo, Enrica Gallenga, Carla, Tetè, Giulia, Kritas, Spyros K., Conti, Pio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236677/
https://www.ncbi.nlm.nih.gov/pubmed/32460208
http://dx.doi.org/10.1016/j.mehy.2020.109856
_version_ 1783536191326388224
author Gigante, Antonio
Aquili, Alberto
Farinelli, Luca
Caraffa, Alessandro
Ronconi, Gianpaolo
Enrica Gallenga, Carla
Tetè, Giulia
Kritas, Spyros K.
Conti, Pio
author_facet Gigante, Antonio
Aquili, Alberto
Farinelli, Luca
Caraffa, Alessandro
Ronconi, Gianpaolo
Enrica Gallenga, Carla
Tetè, Giulia
Kritas, Spyros K.
Conti, Pio
author_sort Gigante, Antonio
collection PubMed
description A novel human coronavirus SARS‐CoV‐2 (also referred to as CoV-19) that emerged in late 2019 causes Covid-19 disease a respiratory tract infection which provokes about 4 million deaths per year. Unfortunately, to date, there is no specific antiviral treatment for COVID-19. Mast cells (MCs) are immune cells implicated in the pathogenesis of viral infections, where they mediate inflammation. Microbes, including virus, activate MCs through TLR releasing chemical pro-inflammatory compounds and cytokines. Although, in biomedical literature there are only few reports on MCs activation by SARS-CoV-2 infection. The production of pro-inflammatory cytokines by MC viral activation leads to increase pulmonary inflammation and fibrosis. Sodium Chromo-Glycate (SCG) described as a MC stabilizer, prevents the release of inflammatory chemical compounds, improve mouse survival and respiratory pathological changes in lung viral infection and suppresses inflammation. Furthermore, palmitoylethanolamide (PEA) a nuclear factor agonist, an endogenous fatty acid amide, which exerts a variety of biological effects, related to chronic inflammation and pain, is involved also in MCs homeostasis with an inhibitory and protective effect on the respiratory tract during viral infections. Here, we hypothesize for the first time, that SCG and/or PEA suppress MC activation and pro-inflammatory mediators release, playing an anti-inflammatory therapeutic role in the inflamed lung of patients with COVID-19.
format Online
Article
Text
id pubmed-7236677
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72366772020-05-19 Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 Gigante, Antonio Aquili, Alberto Farinelli, Luca Caraffa, Alessandro Ronconi, Gianpaolo Enrica Gallenga, Carla Tetè, Giulia Kritas, Spyros K. Conti, Pio Med Hypotheses Article A novel human coronavirus SARS‐CoV‐2 (also referred to as CoV-19) that emerged in late 2019 causes Covid-19 disease a respiratory tract infection which provokes about 4 million deaths per year. Unfortunately, to date, there is no specific antiviral treatment for COVID-19. Mast cells (MCs) are immune cells implicated in the pathogenesis of viral infections, where they mediate inflammation. Microbes, including virus, activate MCs through TLR releasing chemical pro-inflammatory compounds and cytokines. Although, in biomedical literature there are only few reports on MCs activation by SARS-CoV-2 infection. The production of pro-inflammatory cytokines by MC viral activation leads to increase pulmonary inflammation and fibrosis. Sodium Chromo-Glycate (SCG) described as a MC stabilizer, prevents the release of inflammatory chemical compounds, improve mouse survival and respiratory pathological changes in lung viral infection and suppresses inflammation. Furthermore, palmitoylethanolamide (PEA) a nuclear factor agonist, an endogenous fatty acid amide, which exerts a variety of biological effects, related to chronic inflammation and pain, is involved also in MCs homeostasis with an inhibitory and protective effect on the respiratory tract during viral infections. Here, we hypothesize for the first time, that SCG and/or PEA suppress MC activation and pro-inflammatory mediators release, playing an anti-inflammatory therapeutic role in the inflamed lung of patients with COVID-19. Elsevier Ltd. 2020-10 2020-05-19 /pmc/articles/PMC7236677/ /pubmed/32460208 http://dx.doi.org/10.1016/j.mehy.2020.109856 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Gigante, Antonio
Aquili, Alberto
Farinelli, Luca
Caraffa, Alessandro
Ronconi, Gianpaolo
Enrica Gallenga, Carla
Tetè, Giulia
Kritas, Spyros K.
Conti, Pio
Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
title Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
title_full Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
title_fullStr Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
title_full_unstemmed Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
title_short Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
title_sort sodium chromo-glycate and palmitoylethanolamide: a possible strategy to treat mast cell-induced lung inflammation in covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236677/
https://www.ncbi.nlm.nih.gov/pubmed/32460208
http://dx.doi.org/10.1016/j.mehy.2020.109856
work_keys_str_mv AT giganteantonio sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19
AT aquilialberto sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19
AT farinelliluca sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19
AT caraffaalessandro sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19
AT ronconigianpaolo sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19
AT enricagallengacarla sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19
AT tetegiulia sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19
AT kritasspyrosk sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19
AT contipio sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19